

## **Clinical Study Seeks Allergic Asthma Patients with Uncontrolled Symptoms**

If allergic asthma symptoms disrupt your life, despite treatment, read on to learn more.

Allergic asthma is the most common form of asthma and affects 60 percent of the 20 million Americans living with the condition. Allergic asthma is triggered by allergens such as pet dander, dust mites, cockroaches, and mold and mildew.

A clinical research study is seeking participants between the ages of 12 and 75 with moderate to severe persistent allergic asthma that is inadequately controlled with a standard treatment combination of high-dose inhaled corticosteroids and long-acting beta-agonists, such as those in the combination drug Advair®.

The EXTRA Study will evaluate if subcutaneous injections of an investigational drug given as add-on therapy to standard asthma treatments can safely and effectively reduce the number of asthma attacks and improve asthma symptoms in patients with moderate to severe persistent allergic asthma.

Patients who qualify for participation after a two- to four-week observational period will have a 50 percent chance of being assigned to one of the study's two treatment groups. One group will receive standard treatment plus the investigational drug for 48 weeks, while the other group will receive standard treatment plus placebo for 48 weeks. Placebo is a solution that looks like the study drug but does not contain the study drug.

If you, or someone you know, may be interested in enrolling, speak with your doctor or call 1-888-662-6728 to find out if there is a participating medical facility near you.